Edesa Biotech ((EDSA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The JUST BREATHE study, officially titled ‘Phase 2 Clinical Platform Trial Investigating Multiple Therapeutic Options for the Treatment of Hospitalized Patients With Acute Respiratory Distress Syndrome (ARDS),’ aims to evaluate the safety and efficacy of various host-directed therapeutics for ARDS. This study is significant as it explores innovative treatment options for a condition with high mortality rates, potentially improving patient outcomes.
The intervention being tested in this study is vilobelimab, an experimental drug administered intravenously. It is designed to treat hospitalized patients with ARDS by potentially reducing inflammation and improving respiratory function.
This Phase 2 study is interventional, with a randomized, parallel assignment model. It employs triple masking to ensure unbiased results, with the primary purpose of treatment. Participants are randomly assigned to receive either vilobelimab or a placebo.
The study began on June 21, 2025, with an estimated primary completion date yet to be announced. The last update was submitted on July 10, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The market implications of this study are significant for Edesa Biotech and its collaborators. Positive outcomes could boost investor confidence and stock performance, especially given the competitive landscape in ARDS treatment development. Investors should monitor updates closely as they could influence market dynamics.
The study is currently ongoing, with further details available on the ClinicalTrials portal.